Delayed recovery of speech discrimination after fractionated stereotactic radiotherapy for vestibular schwannoma in neurofibromatosis 2

February 12, 2014
| Reprints


Hearing loss commonly occurs after radiation therapy for an acoustic neuroma, and it is highly unusual for hearing to return after a prolonged period of time. We report the case of a 12-year-old boy with neurofibromatosis 2 who underwent fractionated stereotactic radiotherapy for the treatment of a left-sided vestibular schwannoma. Following treatment, he demonstrated an elevation of pure-tone audiometric thresholds and a sudden decrease in speech discrimination score (SDS) to 0%. However, 20 months postoperatively, his SDS suddenly and spontaneously rose to 92%, although there was no improvement in his speech reception threshold. We discuss the possible reasons for the unusual outcome in this patient.


Neurofibromatosis type 2 (NF-2) is a genetic disorder caused by a mutation in the merlin gene located on chromosome 22. Absence of the merlin tumor-suppressor gene results in the development of bilateral vestibular schwannomas and other intracranial and spinal tumors, including meningiomas and ependymomas. The management of vestibular schwannoma in patients with NF-2 has been controversial. Patients often experience bilateral deafness either from the tumors themselves or from extirpative surgery.

ENT Journal provides full text articles to our registered members.
Please log in or sign up for a FREE membership to view the full content:

You may also like to: